Filing Flows › Bolt Biotherapeutics (BOLT) › Q1 2025
Bolt Biotherapeutics (BOLT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Bolt Biotherapeutics (BOLT) reported revenue of $1.2M for the first quarter 2025 (Q1 2025), -77% from a year earlier. Operating margin was -991.4%, net loss $11.0M (903.4% of revenue).
Bolt Biotherapeutics, Q1 2025: revenue $1.2M (-77% year over year), operating margin -991.4%, net loss $11.0M, operating cash flow −$13.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | — | -77% |
| Operating profit | −$12.1M | — | — |
| Net earnings | −$11.0M | — | — |
| Operating cash flow | −$13.4M | — | — |
What changed
Revenue was $1.2M in Q1 2025, down 77% year over year.
Operating costs exceeded revenue by $12.1M, an operating margin of -991.4%. Total costs fell 40% while revenue fell 77%. The quarter ended with a net loss of $11.0M.
Operating cash flow was −$13.4M. Non-cash charges added back $399K of depreciation and amortization and $709K of share-based compensation. Working capital and other items used $3.4M.
Questions
What was Bolt Biotherapeutics' revenue in the first quarter 2025?
Bolt Biotherapeutics (BOLT) reported revenue of $1.2M for the first quarter 2025 (Q1 2025), -77% from a year earlier.
Was Bolt Biotherapeutics profitable in the first quarter 2025?
Operating loss was $12.1M (-991.4% of revenue) and net loss $11.0M.